Does aspirin use reduce the risk for cancer?

被引：11

作者：

Iqbal, Usman ^{[1
,2
]}

Yang, Hsuan-Chia ^{[2
,3
]}

Jian, Wen-Shan ^{[2
,4
]}

Yen, Yun ^{[5
,6
]}

Li, Yu-Chuan ^{[2
,5
,7
]}

机构：

[1] Taipei Med Univ, Coll Publ Hlth, Masters Program, Global Hlth & Dev Dept, Taipei, Taiwan

[2] Int Ctr Hlth Informat Technol, Taipei, Taiwan

[3] Natl Yang Ming Univ, Inst Biomed Informat, Taipei, Taiwan

[4] Taipei Med Univ, Sch Hlth Care Adm, Coll Management, Taipei, Taiwan

[5] Taipei Med Univ, Coll Med Sci & Technol, Taipei, Taiwan

[6] City Hope Natl Med Ctr, Duarte, CA USA

[7] Wan Fang Hosp, Dept Dermatol, Taipei, Taiwan

来源：

JOURNAL OF INVESTIGATIVE MEDICINE | 2017年 / 65卷 / 02期

关键词：

Aspirin; Cancer; Drugs; Investigational; Drug-Related Side Effects and Adverse Reactions; Carcinogenesis; PREVENT COLORECTAL ADENOMAS; RANDOMIZED-TRIAL;

D O I：

10.1136/jim-2016-000275

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99%) Taiwanese from 2001 to 2011. This was a case-control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0.97; 95% CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95% CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to the discussion on aspirin's safety profile.

引用

页码：391 / 392

页数：2

共 10 条

[1] A randomized trial of aspirin to prevent colorectal adenomas
Baron, JA
Cole, BF
Sandler, RS
Haile, RW
Ahnen, D
Bresalier, R
McKeown-Eyssen, G
Summers, RW
Rothstein, R
Burke, CA
Snover, DC
Church, TR
Allen, JI
Beach, M
Beck, GJ
Bond, JH
Byers, T
Greenberg, ER
Mandel, JS
Marcon, N
Mott, LA
Pearson, L
Saibil, F
van Stolk, RU
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) : 891 - 899
[2] A comparison of observational studies and randomized, controlled trials.
Benson, K
Hartz, AJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) : 1878 - 1886
[3] Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer
Cao, Yin
Nishihara, Reiko
Wu, Kana
Wang, Molin
Ogino, Shuji
Willett, Walter C.
Spiegelman, Donna
Fuchs, Charles S.
Giovannucci, Edward L.
Chan, Andrew T.
[J]. JAMA ONCOLOGY, 2016, 2 (06) : 762 - 769
[4] Aspirin use and the risk of cholangiocarcinoma
Choi, Jonggi
Ghoz, Hassan M.
Peeraphatdit, Thoetchai
Baichoo, Esha
Addissie, Benyam D.
Harmsen, William S.
Therneau, Terry M.
Olson, Janet E.
Chaiteerakij, Roongruedee
Roberts, Lewis R.
[J]. HEPATOLOGY, 2016, 64 (03) : 785 - 796
[5] Aspirin and colorectal cancer: the promise of precision chemoprevention
Drew, David A.
Cao, Yin
Chan, Andrew T.
[J]. NATURE REVIEWS CANCER, 2016, 16 (03) : 173 - 186
[6] Associations Between the Use of Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs and Colorectal Cancer Risk
Friis, S.
Riis, A. H.
Erichsen, R.
Baron, J. A.
Sorensen, H. T.
[J]. ANNALS OF INTERNAL MEDICINE, 2015, 163 (05)
[7] Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants
Nan, Hongmei
Hutter, Carolyn M.
Lin, Yi
Jacobs, Eric J.
Ulrich, Cornelia M.
White, Emily
Baron, John A.
Berndt, Sonja I.
Brenner, Hermann
Butterbach, Katja
Caan, Bette J.
Campbell, Peter T.
Carlson, Christopher S.
Casey, Graham
Chang-Claude, Jenny
Chanock, Stephen J.
Cotterchio, Michelle
Duggan, David
Figueiredo, Jane C.
Fuchs, Charles S.
Giovannucci, Edward L.
Gong, Jian
Haile, Robert W.
Harrison, Tabitha A.
Hayes, Richard B.
Hoffmeister, Michael
Hopper, John L.
Hudson, Thomas J.
Jenkins, Mark A.
Jiao, Shuo
Lindor, Noralane M.
Lemire, Mathieu
Le Marchand, Loic
Newcomb, Polly A.
Ogino, Shuji
Pflugeisen, Bethann M.
Potter, John D.
Qu, Conghui
Rosse, Stephanie A.
Rudolph, Anja
Schoen, Robert E.
Schumacher, Fredrick R.
Seminara, Daniela
Slattery, Martha L.
Thibodeau, Stephen N.
Thomas, Fridtjof
Thornquist, Mark
Warnick, Greg S.
Zanke, Brent W.
Gauderman, W. James
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (11): : 1133 - 1142
[8] Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection
Rüschoff, J
Wallinger, S
Dietmaier, W
Bocker, T
Brockhoff, G
Hofstädter, F
Fishel, R
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (19) : 11301 - 11306
[9] A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
Sandler, RS
Halabi, S
Baron, JA
Budinger, S
Paskett, E
Keresztes, R
Petrelli, N
Pipas, JM
Karp, DD
Loprinzi, CL
Steinbach, G
Schilsky, R
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) : 883 - 890
[10] Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents
Wong, C. C.
Cheng, Ka-Wing
Rigas, Basil
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (03) : 572 - 578

← 1 →